ClinicalTrials.gg
RecruitingNCT05623722Updated Sep 8, 2025

Erector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury

An interventional study of Erector spinae plane block in Sepsis, Acute Gastrointestinal Injury and Organ Dysfunction Syndrome, sponsored by Jing Cai, MD. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Jing Cai, MD · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.

Planned enrollment
62nd of 121
116 · median 118
Started
2022
with 28 others
No phase
67 of 286
28 open now
Primary completion
2026-11
later than 49 of 105 live
Registered
167th of 286
by date

Among the 286 studies in Sepsis with a site in China, this one is the 62nd largest by planned enrollment of the 121 interventional ones that give a count, is one of 29 that started in 2022, is one of 67 with no phase, reaches primary completion later than 49 of the 105 other live ones, and was the 167th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 286 studies in Sepsis with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, parallel-group, open-label, randomized controlled clinical trial. Sepsis is defined as organ dysfunction induced by infections. And sepsis and gastrointestinal injury can be the leading cause for each other. Our previous study showed erector spinae plane block improved the organ dysfunctions in patients with AGI. The aim of the clinical trial is to investigate erector pinae plane block improves the organ dysfunction in septic patients with acute gastrointestinal injury.

03

Conditions studied

  • Sepsis
  • Acute Gastrointestinal Injury
  • Organ Dysfunction Syndrome

Browse trials for

Keywords

  • Sepsis
  • Acute Gastrointestinal Injury
  • Organ Dysfunction Syndrome
  • Erector spinae plane block
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Septic patients with acute gastrointestinal injury grade II or III;
  • Age over 18 years;
  • Expected to stay in the ICU for at least 3 days or longer;

Exclusion criteria

Exclusion Criteria:

  • Mean arterial pressure less than 65 mmHg after fluid resuscitation, or requirement for an intravenous norepinephrine dose of greater than 0.5 µg/kg/min to maintain a normal mean arterial pressure;
  • Heart rates less than 50 beats/min, or concomitant with moderate-to-severe atrioventricular block without a pacemaker;
  • for erector spinae plane blocks, including infection of the puncture site, spinal diseases or immobilization;
  • Primary gastrointestinal disorders requiring a surgical procedure, such as mechanical intestinal obstruction, massive gastrointestinal hemorrhage, and gastrointestinal perforation;
  • Gastrointestinal operation within one week before enrollment;
  • Neuromuscular disorders;
  • Coagulation abnormalities:activated or prothrombin time is prolonged with 2 folds, or count less than 50×109/L;
  • End-stage malignant tumor or cachexia;
  • History of allergy to amide anesthetics;
  • Known pregnancy;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • No intervention
    Control Group

    Patients receive the same administration of acute gastrointestinal injury and enteral nutrition strategy according to the guidelines, and the routine practice of the ICU. The interventions end on day 7 or cease when the patients are discharged from the ICU, dead, or withdraw their consent.

  • Experimental
    Erector Spinae Plane Block Group

    1. Patients receive the same administration of acute gastrointestinal injury and enteral nutrition strategy according to the guidelines, and the routine practice of the ICU. 2. Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The interventions end on day 7 or cease when the patients are discharged from the ICU, dead, or withdraw their consent.

    Procedure: Erector spinae plane block

Interventions

  • ProcedureErector spinae plane block

    Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The intervention ends on day 7 or ceases when the patient is discharged from the ICU, died, or withdrew their consent.

    Also known as: Regional nerve block

06

What researchers measure

Primary outcomes

  1. Sequential Organ Failure Assessment (SOFA) score

    Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score. The mininum value is 0 score, and the maximum value is 24 scores. The higher scores mean a worse outcome.

    Time frame: on the day 7 after enrollment

Secondary outcomes

  1. SOFA score

    Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score. The mininum value is 0 score, and the maximum value is 24 scores. The higher scores mean a worse outcome.

    Time frame: on the day 3 after enrollment

  2. Remission rate of AGI

    The remission of AGI is defined as a decrease of more than one grade in AGI grades. The remission rate is the percentage of remission in the same cohort.

    Time frame: on the day 3 and 7 after enrollment

  3. 28-day all-cause mortality

    All-cause mortality on the day 28 from enrollment

    Time frame: on the day 28 after enrolment

Other outcomes

  1. Indexes of intestinal mucosal damage

    D-lactic acid,intestinal fatty acid binding protein in the serum

    Time frame: on the day 3 and 7 after enrollment

  2. Gut microbiota diversity

    The fecal DNA is obtained from peri-rectal swabs and analyzed for gut microbiota diversity.

    Time frame: on the day 3 and 7 after enrollment

  3. Catecholamine

    Epinephrine,norepinephrine, dopamine and vanillylmandelic acid in the serum.

    Time frame: on the day 3 and 7 after enrollment

07

Study locations

1 of 1 sites recruiting
  • Department of Intensive Care Medicine of Zhujiang Hospital,Southern Medical University
    Guangzhou, Guangdong 510282, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication are to be shared.

Supporting information: Study protocol

Time frame: This are to be provided as a date relative to the time when summary data are published.

Access criteria: The data will be made available upon reasonable request by the corresponding author. A proposal with a detailed description of the study objectives and a plan for statistical analysis will be required for the evaluation of the reasonability of requests. Additional materials may also be required during the process of request evaluation. The data of deidentified participants will be provided after approval by the corresponding authors and the Zhujiang Hospital of Southern Medical University.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Nov 2026, 47 months after the start.

Of 303 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 47 months is above that.

Counting every sponsor, half of 326 studies reached it within 22 months; a quarter within 11 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2022
First posted
Nov 21, 2022
StartActual
Dec 29, 2022
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05623722
Lead sponsor
Jing Cai, MD
Collaborators
Zhongshan People's Hospital, Guangdong, China, Zhongshan Hospital Of Traditional Chinese Medicine
Responsible party
Jing Cai, MD (Attending physician, Zhujiang Hospital) — Sponsor-investigator
First posted
Nov 21, 2022
Start date
Dec 29, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 8, 2025

Study contacts

Jing Cai, MD
Contact
caijing78@hotmail.com
+86-02062782927
Jing Cai
principal investigator · Department of Intensive Care Medicine, Zhujiang Hospital, Southern Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion